Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe
Background Creating new therapies often involves drug companies paying healthcare professionals and institutions for research and development (R&D) activities, including clinical trials. However, industry sponsorship can create conflicts of interest (COIs). We analysed approaches to drug compan...
Saved in:
Main Authors: | Piotr Ozieranski (Author), Luc Martinon (Author), Pierre-Alain Jachiet (Author), Shai Mulinari (Author) |
---|---|
Format: | Book |
Published: |
Kerman University of Medical Sciences,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Scurvy as the tip of the iceberg
by: Sarah Hasan Al-Breiki, et al.
Published: (2014) -
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
by: Piotr Ozieranski, et al.
Published: (2023) -
Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?
by: Yurie Kobashi, et al.
Published: (2019) -
The tip of the iceberg: postpartum suicidality in Israel
by: Saralee Glasser, et al.
Published: (2018) -
Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
by: Alice Fabbri, et al.
Published: (2018)